Gapping up
In reaction to earnings/guidance:
- VCSA +24.3%, MTTR +19.7%, ENVX +19.1%, DDS +18.7%, VZIO +11.1%, NOTV +11%, ACHR +8.7%, DIS +8.6% (also will launch ad-supported tier for Disney+ on Dec. 8; also ups prices for no-ads options), STKL +8.2%, UTZ +8.2%, PRVA +7.9%, PRMW +7.1%, DCBO +6.5%, BROS +6.2%, DTC +6.1%, KELYA +5.6%, CPNG +5.3%, GLNG +4.1%, EQRX +3.5%, STAA +3.3%, AOSL +3.3%, DHT +2.8%, AIT +2.8%, SGHC +2.3%, AER +2.2%, FNV +1.7%, GOOS +1.5%
Other news:
- LHDX +5% (announced that Health Canada has granted Authorization under Interim Order for the emergency use and commercialization of the first and only at-home test for COVID & Flu)
- COIN +3.1% (being investigated over staking programs according to Bloomberg)
- JHX +2.6% (provides Chairperson succession plan)
- ARGX +2% (EC grants marketing authorization for VYVGART)
- DNA +1.9% (Synlogic (SYBX) announced a new drug candidate for the treatment of gout developed in partnership with Ginkgo Bioworks)
- EVGO +1.8% (files for $750 mln mixed securities shelf offering; also stock offering)
- VCTR +1.5% (reports July AUM)
- NTRA +1.3% (files pre-submission to FDA for its Panorama non-invasive prenatal test)
- NL +1.1% (special dividend of $0.35/sh)
- ECOM +1.1% (announces integration with Shopee)
Analyst comments:
- FSLR +2.6% (upgraded to Overweight from Sector Weight at KeyBanc Capital Markets)
- ATY +2.3% (upgraded to Buy from Neutral at ROTH Capital)